Tectonic Therapeutic, Inc.

TX45 Phase 1a results show favorable safety profile and impact on renal plasma flow, supporting further development for PH-HFpEF. Upcoming Phase 1b and APEX Phase 2 trial data expected in 2025 and 2026, respectively.

Septerna, a GPCR-focused biotech, priced a $288 million IPO, selling 16 million shares at $18 each. The company raised over $200 million in private funding and plans to use IPO proceeds to advance its lead drug SEP-786 for hypoparathyroidism and SEP-631 for chronic spontaneous urticaria. This marks the 23rd biotech IPO of the year, with investors showing continued interest in clinical-stage biotechs.

Avisol Capital Partners, a team of medical experts, finance professionals, and techies, invests their own money in biopharma picks, aiming to balance value and growth investing. They offer a monthly updated catalyst database, an investability scoring system, and direct chat access through their Total Pharma Tracker.

Tectonic Therapeutic reports favorable Phase Ia trial data for TX45, its lead asset for treating Group 2 pulmonary hypertension-heart failure with preserved ejection fraction (PH-HFpEF). The trial assessed safety, tolerability, and pharmacokinetic/pharmacodynamics (PK/PD) in healthy subjects, revealing minimal adverse events and no immune-mediated clearance. A strong PK/PD relationship was established, guiding Phase II dose selection. The Phase II APEX trial, now underway, will randomize patients to different TX45 regimens or placebo, with topline results expected in 2026.